Background.
Community-acquired bacterial pneumonia (CABP) is a serious infection in many patients.
Ceftaroline fosamil (CPT-F) is approved for the treatment of CABP and acute bacterial
skin and skin structure infections in the US, and for similar indications in the EU.
CAPTURE is a multicenter registry study describing patients treated with CPT-F in
the US.
Methods.
Data were collected at participating centers by randomly ordered chart review between
September 2011 and February 2014, which included demographics, disease characteristics,
antibiotic use, location of care, and clinical response. Evaluable patients (pts)
were those with a clinical outcome determined.
Results.
649 pts were evaluable. Demographics and co-morbidities are presented in the table.
On diagnosis 81% of pts had 2 or more signs and symptoms; most common were dyspnea
(76%), cough (65%), abnormal auscultatory findings (63%), and sputum production (46%).
At initiation of CPT-F treatment, 35% were located in an intensive care unit (ICU).
84% received prior antibiotics; most commonly ceftriaxone (35%), vancomycin (31%),
azithromycin (27%) and levofloxacin (26%). The mean duration of CPT-F therapy was
6.1 days (SD ± 3.8). Concurrent antibiotics were used in 64% and included azithromycin
(23%), levofloxacin (17%) and vancomycin (8%). Overall clinical success was 83%; 73%
in the ICU and 88% in the ward. Clinical success with CPT-F monotherapy was 84%, and
with concurrent therapy, 83%. Clinical success was 85% for CPT-F as first line therapy
and 83% as 2nd line therapy. CPT-F was discontinued in 8 (1%) pts due to an adverse
event. The majority of pts were discharged to home (60%) or to another healthcare
facility (35%).
Demographics and Co-morbidities
Pts (N=649) n (%)
Males, Females
315 (49)334 (51)
Age, years, mean (SD), range
63.4 (17.5)18–99
Pts with co-morbidities
514 (79)
Structural lung disease
276 (43)
Smoking
223 (34)
Gastroesophageal reflux
146 (22)
Prior pneumonia
159 (24)
Congestive heart failure
134 (21)
Cerebrovascular accident
53 (8)
Alcoholism
54 (8)
Conclusion.
Contemporary clinical use of CPT-F for treating CABP show high rates of clinical
success including pts in the ICU. CAPTURE data support the use of CPT-F as an important
antibiotic for treatment of complicated CABP.
Disclosures.
L. B. Johnson, Forest Laboratories: Investigator, Research support C. M. Cannon, Forest
Laboratories: Investigator and Speaker's Bureau, Research support and Speaker honorarium
L. E. Johnson, Forest Laboratories: Investigator, Research support S. Wallace, Forest
Laboratories: Shareholder, have owned approximately $25,000 in stock in Forest Laboratories,
purchased long before any involvement with this project A. Jandourek, Cerexa Inc.:
Employee, Salary H. D. Friedland, Forest Laboratories: Employee and Shareholder, Salary